Editor’s Note Archive

As we go to press, the Pfizer-AstraZeneca deal is called off for now but that story is far from over

Above revenues and reputation, is patient health and safety. If that's compromised, everything is lost

As we await the US Trade Representative's annual Special 301 Report, stakeholders on both sides of the fence seem to be hardening…

Last month, the US FDA has reportedly issued 483s to at least three more pharmaceutical companies in India, one of them the Indian…

“If we are interested in exporting medicines, we have to also import the standards.”

Name-Shame-Blame-Train. This has been the pharmaceutical industry's mantra to manage non-compliance

After visiting the Taj Mahal on her recent visit to India, FDA Commissioner Margaret A Hamburg blogged, “those responsible for…

Blogging about her recent trip to India, Margaret Hamburg, Commissioner of the US Food and Drug Administration (FDA) spoke about…

As we go to press with this special issue focussing on the biotechnology sector in India, Biocon's Q3 results seem like a light at…

After hanging fire for the past few months, the Department of Industrial Policy and Promotion (DIPP) has finally given some…